Abstract
Summary
We investigated whether repeat BMD measurements in clinical populations are useful for fracture risk assessment. We report that repeat BMD measurements are a robust predictor of fracture in clinical populations; this is not affected by preceding BMD change or recent osteoporosis therapy.
Introduction
In clinical practice, many patients selectively undergo repeat bone mineral density (BMD) measurements. We investigated whether repeat BMD measurements in clinical populations are useful for fracture risk assessment and whether this is affected by preceding change in BMD or recent osteoporosis therapy.
Methods
We identified women and men aged ≥50 years who had a BMD measurement during 1990–2009 from a large clinical BMD database for Manitoba, Canada (n = 50,215). Patient subgroups aged ≥50 years at baseline with repeat BMD measures were identified. Data were linked to an administrative data repository, from which osteoporosis therapy, fracture outcomes, and covariates were extracted. Using Cox proportional hazards models, we assessed covariate-adjusted risk for major osteoporotic fracture (MOF) and hip fracture according to BMD (total hip, lumbar spine, femoral neck) at different time points.
Results
Prevalence of osteoporosis therapy increased from 18 % at baseline to 55 % by the fourth measurement. Total hip BMD was predictive of MOF at each time point. In the patient subgroup with two repeat BMD measurements (n = 13,481), MOF prediction with the first and second measurements was similar: adjusted-hazard ratio (HR) per SD 1.45 (95 % CI 1.34–1.56) vs. 1.64 (95 % CI 1.48–1.81), respectively. No differences were seen when the second measurement results were stratified by preceding change in BMD or osteoporosis therapy (both p-interactions >0.2). Similar results were seen for hip fracture prediction and when spine and femoral neck BMD were analyzed.
Conclusion
Repeat BMD measurements are a robust predictor of fracture in clinical populations; this is not affected by preceding BMD change or recent osteoporosis therapy.
Similar content being viewed by others
References
WHO (2007) Prevention and management of osteoporosis: report of a WHO scientific group. In: World Health Organisation Scientific Group on the prevention and management of osteoporosis
WHO (2003) The burden of musculoskeletal conditions at the start of the new millennium. In: Geneva; World Health Organisation
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fracture. BMJ Open 312:1254–1259
Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX and its applications to clinical practice. Bone 44:734–743
Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 27:1243–1251
NOF (2014) 2014 clinician’s guide to prevention and treatment of osteoporosis. In: National Osteoporosis Foundation. NOF Accessed 17 October 2014
Compston J (2009) Monitoring osteoporosis treatment. Best Pract Res Clin Rheumatol 23:781–788
Watts NB, Lewiecki EM, Bonnick SL, Laster AJ, Binkley N, Blank RD, Geusens PP, Miller PD, Petak SM, Recker RR, Saag KG, Schousboe J, Siris ES, Bilezikian JP (2009) Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res 24:1643–1646
Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse RG, Prior JC, Kreiger N, Tenenhouse A, Goltzman D (2009) Association between change in BMD and fragility fracture in women and men. J Bone Miner Res 24:361–370
Ahmed LA, Emaus N, Bernsten GK, Bjornerem A, Fonnebo V, Jorensen L, Schirmer H, Stormer J, Joakimsen RM (2010) Bone loss and the risk of non-vertebral fractures in women and men: the Tromso study. Osteoporos Int 21:1503–1511
Hillier TA, Stone KL, Bauer DC, Rizzo JH, Pedula KL, Cauley JA, Ensrud KE, Hochberg MC, Cummings SR (2007) Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med 167:155–160
Nguyen TV, Centre JR, Eisman JA (2005) Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res 20:1195–1201
Leslie WD, Morin SN, Lix LM (2012) Rate of bone density change does not enhance fracture prediction in routine clinical practice. J Clin Endocrinol Metab 97:1211–1218
Berry SD, Samelson EJ, Pencina MJ, McLean RR, Cupples A, Broe KE, Kiel DP (2013) Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture. JAMA Intern Med 310:1256–1262
Leslie WD, Tsang JF, Caetano PA, Lix LM, For the Manitoba Bone Density Program (2007) Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 92:77–81
Lewiecki EM, Cummings SR, Cosman F (2012) Treat-to-target for osteoporosis: is now the time? J Clin Endocrinol Metab 98:946–953
McCloskey E, Leslie WD (2013) Goal directed therapy in osteoporosis. J Bone Miner Res 28:439–441
Leslie WD, Caetano PA, MacWilliam LR et al (2005) Construction and validation of a population-based bone densitometry database. J Clin Densitom 8:25–30
Roos NP (1999) Establishing a population data-based policy unit. Med Care 37:JS15–JS26
Roos NP, Shapiro E (1999) Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care 37:JS10–JS14
Leslie WD, Metge C (2003) Establishing a regional bone density program: lessons from the Manitoba experience. J Clin Densitom 6:275–282
Gluer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK (1995) Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 5:262–270
Shepherd JA, Lu Y, Wilson K, Fuerst T, Genant H, Hangartner TN, Wilson C, Hans D, Leib ES (2006) Cross-calibration and minimum precision standards for duak-energy X-ray absorptiometry: the 2005 ISCD Official Positions. J Clin Densitom 9:31–36
Leslie WD (2008) Factors affecting short-term bone density precision assessment and the effect on patient monitoring. J Bone Miner Res 23:199–204
Kozyrskyj AL, Mustard CA (1998) Validation of an electronic, population-based prescription database. Ann Pharmacother 32:1152–1157
Hamilton R, Briceland L (1992) Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm 46:1691–1696
(2005) U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and the Centers for Medicare and Medicaid Services; U.S. Department of Health and Human Services; Centers for Disease Control and Prevention; Centers for Medicare and Medicaid Services. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), Sixth Edition. Odum Institute V2
(2009) U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and the Centers for Medicare and Medicaid Services; U.S. Department of Health and Human Services; Centers for Disease Control and Prevention; Centers for Medicare and Medicaid Services. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Odum Institute V2
Lix LM, Azimaee M, Osman BA et al (2012) Osteoporosis-related fracture case definitions for population-based administrative data. BMC Public Health 12:301
Brennan SL, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2014) FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporos Int 25:61–69
Brennan SL, Leslie WD, Lix LM (2014) Is lower income associated with an increased likelihood of qualification for treatment for osteoporosis in Canadian women? Osteoporos Int 25:273–279
Fraser LA, Langsetmo L, Berge C, Ionnidis G, Gotzman D, Adachi JD, Papaoiannou A, Josse R, Kovacs CS, Olszynski WP, Towheed T, Hanley DA, Kaiser SM, Prior J, Jamal S, Kreiger N, Brown JP, Johansson H, Oden A, McCloskey E, Kanis JA, Leslie WD, CaMOS Research Group (2011) Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMOS. Osteoporos Int 22:829–837
Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, Manitoba Bone Density Program (2010) Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 25:2350–2358
Leslie WD, Lix LM, Tsang JF, Caetano PA (2007) Single-site vs. multisite bone density measurement for fracture prediction. Arch Intern Med 167:1641–1647
Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, Ransohoff DF, Cauley JA, Ensrud KE, Study of Osteoporotic Fractures Research Group (2012) Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 366:225–233
Kanis JA, McCloskey E, Branco J, Brandi M-L, Dennison E, Devogelaer J-P, Ferrari S, Kaufman J-M, Papapoulos S, Reginster J-Y, Rizzoli R (2014) Goal-directed treatment of osteoporosis in Europe. Osteoporos Int 25:2533–2543
Leslie WD, Majumdar SR, Lix LM, Morin SN, Johansson H, Oden A, McCloskey EV, Kanis JA (2014) Can change in FRAX score be used to “treat-to-target”? A population-based cohort study. J Bone Miner Res 29:1074–1080
Yu EW, Finkelstein JS (2012) Bone density screening intervals for osteoporosis: one size does not fit all. JAMA 307:2591–2592
Acknowledgments
The authors acknowledge the Manitoba Centre for Health Policy (MCHP) for use of data contained in the Population Health Research Data Repository (HIPC project number #2007/2008-49). The results and conclusions are those of the authors, and no official endorsement by the MCHP, Manitoba Health, or other data providers is intended or should be inferred. This article has been reviewed and approved by the members of the Manitoba Bone Density Program Committee.
Conflicts of interest
William Leslie has received Speaker fees from Amgen, Eli Lilly, and Novartis, and Research grants from Amgen, and Genzyme. Suzanne Morin has acted as a Consultant to Amgen and Eli Lilly, and received Research grants from Amgen, and Merck. Sharon Brennan-Olsen and Lisa Lix have nothing to disclose.
Funding
No funding support was received for this research project.
Fellowships
SNM is chercheur-clinicien boursier des Fonds de la Recherche du Québec en Santé. LML is supported by a Manitoba Research Chair. SLB-O is supported by a National Health and Medical Research Council of Australia Early Career Fellowship (1012472, 2011–14) and an Alfred Deakin Postdoctoral Research Fellowship (2015–16).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leslie, W., Brennan-Olsen, S., Morin, S. et al. Fracture prediction from repeat BMD measurements in clinical practice. Osteoporos Int 27, 203–210 (2016). https://doi.org/10.1007/s00198-015-3259-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-015-3259-y